4D Molecular Therapeutics FDMT Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $60.24M-59.7% | $149.34M-40.1% | $249.11M+376% | $52.35M-65.8% | ||
| $342.41M+24.3% | $275.54M+604% | $39.12M-75.7% | $161.2M+70.1% | ||
| $38.98M-0.8% | $39.29M+26.9% | $30.95M+28.7% | $24.05M+25.4% | ||
| $413.13M-5.0% | $434.93M+46.6% | $296.59M+34.5% | $220.51M-14.0% | ||
| $14.87M-23.9% | $19.53M-2.9% | $20.13M-9.6% | $22.26M+54.7% | ||
| $18.14M-13.9% | $21.07M+82.6% | $11.54M-11.8% | $13.09M-10.1% | ||
| $9.19M+116% | $4.26M+523% | $684K-36.7% | $1.08M+79.4% | ||
| $566.71M+1.1% | $560.38M+64.9% | $339.89M+29.8% | $261.85M-25.9% | ||
| $30.87M+106% | $14.96M+5.9% | $14.13M+30.8% | $10.8M-7.9% | ||
| $26.87M+42.4% | $18.87M+57.1% | $12.01M+35.4% | $8.87M+14.5% | ||
| $360K+40.1% | $257K-5.9% | $273K-69.1% | $884K-66.0% | ||
| $5.59M-0.8% | $5.64M+79.0% | $3.15M+18.6% | $2.66M+116% | ||
| $745K-29.5% | $1.06M+8.7% | $972K-9.7% | $1.08M-56.8% | ||
| $43.99M+50.9% | $29.15M+53.8% | $18.95M+20.5% | $15.73M-3.7% | ||
| $15.82M-16.6% | $18.97M+64.6% | $11.52M-14.5% | $13.47M-11.5% | ||
| $21.41M-13.0% | $24.61M+67.7% | $14.67M-9.0% | $16.12M-2.0% | ||
| $138K-28.5% | $193K-22.2% | $248K+1,081% | $21K-82.5% | ||
| $61.05M+22.6% | $49.78M+55.3% | $32.06M+5.1% | $30.51M-11.3% | ||
| $0— | $0— | $0— | $0— | ||
| $6K+20.0% | $5K+25.0% | $4K+33.3% | $3K0.0% | ||
| $1.22B+12.4% | $1.09B+50.3% | $723.14M+32.2% | $547.02M+3.9% | ||
| -$716.3M-24.3% | -$576.2M-38.7% | -$415.33M-32.1% | -$314.49M-51.9% | ||
| $727K+217% | $229K+1,331% | $16K+101% | -$1.2M-183% | ||
| $505.66M-1.0% | $510.61M+65.9% | $307.83M+33.1% | $231.34M-27.5% | ||
| $566.71M+1.1% | $560.38M+64.9% | $339.89M+29.8% | $261.85M-25.9% | ||
| —— | —— | —— | —— | ||
| $342.41M+24.3% | $275.54M+604% | $39.12M-75.7% | $161.2M+70.1% | ||
| $9.19M+116% | $4.26M+523% | $684K-36.7% | $1.08M+79.4% | ||
| $18.14M-13.9% | $21.07M+82.6% | $11.54M-11.8% | $13.09M-10.1% | ||
| $18.14M-13.9% | $21.07M+82.6% | $11.54M-11.8% | $13.09M-10.1% | ||
| $9.19M+116% | $4.26M+523% | $684K-36.7% | $1.08M+79.4% | ||
| $18.14M-13.9% | $21.07M+82.6% | $11.54M-11.8% | $13.09M-10.1% | ||
| $9.19M+116% | $4.26M+523% | $684K-36.7% | $1.08M+79.4% | ||
| $745K-29.5% | $1.06M+8.7% | $972K-9.7% | $1.08M-56.8% | ||
| $26.87M+42.4% | $18.87M+57.1% | $12.01M+35.4% | $8.87M+14.5% | ||
| $26.87M+42.4% | $18.87M+57.1% | $12.01M+35.4% | $8.87M+14.5% | ||
| $358K-12.7% | $410K+11.1% | $369K+74.1% | $212K-0.9% | ||
| $745K-29.5% | $1.06M+8.7% | $972K-9.7% | $1.08M-56.8% | ||
| $358K-12.7% | $410K+11.1% | $369K+74.1% | $212K-0.9% | ||
| $745K-29.5% | $1.06M+8.7% | $972K-9.7% | $1.08M-56.8% | ||
| $21.41M-13.0% | $24.61M+67.7% | $14.67M-9.0% | $16.12M-2.0% | ||
| $1.22B+12.4% | $1.09B+50.3% | $723.14M+32.2% | $547.02M+3.9% | ||
| $6K+20.0% | $5K+25.0% | $4K+33.3% | $3K0.0% | ||
| $0— | $0— | $0— | $0— | ||
| $358K-12.7% | $410K+11.1% | $369K+74.1% | $212K-0.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are 4D Molecular Therapeutics's total assets?
- 4D Molecular Therapeutics (FDMT) holds $512.9M in total assets, down 0.5% year over year.
- How much debt does 4D Molecular Therapeutics have?
- 4D Molecular Therapeutics carries $20.5M in total debt against $451.8M of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does 4D Molecular Therapeutics have?
- 4D Molecular Therapeutics holds $72.5M in cash and equivalents.
- Can 4D Molecular Therapeutics cover its short-term obligations?
- Its current ratio is 9.34 — current assets exceed current liabilities.
- Where does 4D Molecular Therapeutics's balance sheet data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
